Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation



Status:Terminated
Conditions:Neurology
Therapuetic Areas:Neurology
Healthy:No
Age Range:18 - 65
Updated:6/13/2018
Start Date:September 30, 2017
End Date:April 4, 2018

Use our guide to learn which trials are right for you!

A Randomized Double-blind Multicenter Double-dummy Non-inferiority Trial of Inhaled Loxapine and Intramuscular Haloperidol + Lorazepam for the Reduction of Agitation

The primary objective of this study is to determine the noninferiority of inhaled loxapine
compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

The primary objective of this study is to determine the noninferiority of inhaled loxapine
compared to intramuscular haloperidol/lorazepam on agitation reduction at 120 minutes.

Inclusion Criteria:

1. Requires treatment for agitation in the judgment of a physician

2. Patient either pre-consented, has surrogate consent, or able to consent (in cases of
mild agitation).

3. The patient is at least 18 years of age and less than 65 years of age.

4. Patients with known or presumed schizophrenia or bipolar 1 disorder.

Exclusion Criteria:

1. Patients with acute respiratory signs/symptoms (eg, wheezing).

2. Known diagnosis of Chronic Obstructive Pulmonary Disease (COPD) or asthma or taking
meds for asthma or COPD.

3. Female patients who are obviously pregnant or breast-feeding.

4. Medically unstable patients.

5. Patients or surrogates who object to being in the study (even if previously
pre-consented).

6. Physician objection to patient enrollment in the study.

7. Prisoners or incarcerated.
We found this trial at
1
site
529 West Markham Street
Little Rock, Arkansas 72205
(501) 686-7000
Principal Investigator: Michael P Wilson, MD PhD
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
?
mi
from
Little Rock, AR
Click here to add this to my saved trials